University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Biochemistry & Molecular
Biology

Biochemistry & Molecular Biology

2019

Trefoil Factor(s) and CA19.9: A Promising Panel for Early
Detection of Pancreatic Cancer
Rahat Jahan
University of Nebraska Medical Center, rahat.jahan@unmc.edu

Koelina Ganguly
University of Nebraska Medical Center, koelina.ganguly@unmc.edu

Lynette M. Smith
University of Nebraska-Lincoln, lmsmith@unmc.edu

Pranita Atri
University of Nebraska Medical Center, p.atri@unmc.edu

Joseph Carmicheal
University of Nebraska Medical Center, joseph.carmicheal@unmc.edu

See next page for additional authors
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles
Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons

Recommended Citation
Jahan, Rahat; Ganguly, Koelina; Smith, Lynette M.; Atri, Pranita; Carmicheal, Joseph; Sheinin, Yuri;
Rachagani, Satyanarayana; Natarajan, Gopalakrishnan; Brand, Randall E.; Macha, Muzafar A.; Grandgenett,
Paul M.; Kaur, Sukhwinder; and Batra, Surinder K., "Trefoil Factor(s) and CA19.9: A Promising Panel for
Early Detection of Pancreatic Cancer" (2019). Journal Articles: Biochemistry & Molecular Biology. 120.
https://digitalcommons.unmc.edu/com_bio_articles/120

This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

Authors
Rahat Jahan, Koelina Ganguly, Lynette M. Smith, Pranita Atri, Joseph Carmicheal, Yuri Sheinin,
Satyanarayana Rachagani, Gopalakrishnan Natarajan, Randall E. Brand, Muzafar A. Macha, Paul M.
Grandgenett, Sukhwinder Kaur, and Surinder K. Batra

This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/120

EBIOM-02049; No of Pages 11
EBioMedicine xxx (2019) xxx

Contents lists available at ScienceDirect

EBioMedicine
journal homepage: www.ebiomedicine.com

Trefoil factor(s) and CA19.9: A promising panel for early detection
of pancreatic cancer
Rahat Jahan a, Koelina Ganguly a, Lynette M. Smith b, Pranita Atri a, Joseph Carmicheal a, Yuri Sheinin c,
Satyanarayana Rachagani a, Gopalakrishnan Natarajan a, Randall E. Brand d, Muzafar A. Macha a,e,
Paul M. Grandgenett g, Sukhwinder Kaur a,⁎, Surinder K. Batra a,f,g,⁎⁎
a

Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
c
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
d
Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
e
Department of Otolaryngology-Head & Neck Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
f
Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
g
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA
b

a r t i c l e

i n f o

Article history:
Received 21 August 2018
Received in revised form 18 March 2019
Accepted 19 March 2019
Available online xxxx
Keywords:
Biomarker
Trefoil factor
TFF1
TFF2
TFF3
CA19.9
Pancreatic cancer

a b s t r a c t
Background: Trefoil factors (TFF1, TFF2, and TFF3) are small secretory molecules that recently have gained significant attention in multiple studies as an integral component of pancreatic cancer (PC) subtype-speciﬁc gene signature. Here, we comprehensively investigated the diagnostic potential of all the member of trefoil family,
i.e., TFF1, TFF2, and TFF3 in combination with CA19.9 for detection of PC.
Methods: Trefoil factors (TFFs) gene expression was analyzed in publicly available cancer genome datasets,
followed by assessment of their expression in genetically engineered spontaneous mouse model (GEM) of PC
(KrasG12D; Pdx1-Cre (KC)) and in human tissue microarray consisting of normal pancreas adjacent to tumor
(NAT), precursor lesions (PanIN), and various pathological grades of PC by immunohistochemistry (IHC).
Serum TFFs and CA19.9 levels were evaluated via ELISA in comprehensive sample set (n = 362) comprised of
independent training and validation sets each containing benign controls (BC), chronic pancreatitis (CP), and
various stages of PC. Univariate and multivariate logistic regression and receiver operating characteristic curves
(ROC) were used to examine their diagnostic potential both alone and in combination with CA19.9.
Findings: The publicly available datasets and expression analysis revealed signiﬁcant increased expression of
TFF1, TFF2, and TFF3 in human PanINs and PC tissues. Assessment of KC mouse model also suggested upregulated
expression of TFFs in PanIN lesions and early stage of PC. In serum analyses studies, TFF1 and TFF2 were signiﬁcantly elevated in early stages of PC in comparison to benign and CP control group while signiﬁcant elevation in
TFF3 levels were observed in CP group with no further elevation in its level in early stage PC group. In receiver
operating curve (ROC) analyses, combination of TFFs with CA19.9 emerged as promising panel for discriminating
early stage of PC (EPC) from BC (AUCTFF1+TFF2+TFF3+CA19.9 = 0.93) as well as CP (AUCTFF1+TFF2+TFF3+CA19.9 =
0.93). Notably, at 90% speciﬁcity (desired for blood-based biomarker panel), TFFs combination improved
CA19.9 sensitivity by 10% and 25% to differentiate EPC from BC and CP respectively. In an independent blinded
validation set, the combination of TFFs and CA19.9 (AUCTFF1+TFF2+TFF3+CA19.9 = 0.82) also improved the overall
efﬁcacy of CA19.9 (AUCCA19.9 = 0.66) to differentiate EPC from CP proving unique biomarker capabilities of TFFs
to distinguish early stage of this deadly lethal disease.
Interpretation: In silico, tissue and serum analyses validated signiﬁcantly increased level of all TFFs in precursor
lesions and early stages of PC. The combination of TFFs enhanced sensitivity and speciﬁcity of CA19.9 to discriminate early stage of PC from benign control and chronic pancreatitis groups.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: TFF1, Trefoil Factor 1; TFF2, Trefoil Factor 2; TFF3, Trefoil Factor 3; CA19.9, Cancer Antigen 19.9; AUC, Area under the ROC curve; SN, Sensitivity; SP, Speciﬁcity; ROC,
Receiver Operating Curve; PC, Pancreatic Cancer; BC, Benign Cancer; CP, Chronic Pancreatitis; EPC, Early Pancreatic Cancer; LPC, Late Pancreatic Cancer.
⁎ Correspondence to: S. Kaur, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 985870, Nebraska Medical Center, Omaha, NE, 68198-5870,
USA.
⁎⁎ Correspondence to: S. K. Batra, Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center,
985870, Nebraska Medical Center, Omaha, NE 68198-5870, USA.
E-mail addresses: skaur@unmc.edu (S. Kaur), sbatra@unmc.edu (S.K. Batra).

https://doi.org/10.1016/j.ebiom.2019.03.056
2352-3964/© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: R. Jahan, K. Ganguly, L.M. Smith, et al., Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic
cancer, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019.03.056

2

R. Jahan et al. / EBioMedicine xxx (2019) xxx

Research in context
Evidence before this study
Pancreatic cancer (PC) subtype studies highlight the upregulation
of all the members of Trefoil Factors (TFF1, TFF2, and TFF3) in
classical subtypes of pancreatic cancer. Further, global
transcriptomic studies indicate differential expression of TFFs in
precursor lesion and pancreatic cancer cases. However, to date,
there is no comprehensive study exploring the diagnostic potential
of all Trefoil Factors in pancreatic cancer. We searched in PubMed
and Google Scholar for papers published before Aug 10, 2018,
with the terms “biomarker Trefoil Factors in pancreatic cancer”
OR “diagnostic significance of trefoil factor in pancreatic cancer”
OR “TFF1, TFF2 and TFF3 in pancreatic cancer” with no language
restrictions. TFF1 emerged as an urinary biomarker for early detection of PC in combinatorial panel with LYVE-1, REG1A. To our
knowledge, there is no published study that explores the diagnostic potential all Trefoil Factors alone or in combination with
CA19.9 to diagnose PC utilizing serum/plasma samples.
Added value of this study
Comprehensive analyses of gene datasets, human pancreatic precursor lesions, and tumor tissues revealed differential expression
of all the members of TFF family, i.e. TFF1, TFF2, and TFF3, in
precursor lesions and during the progression of PC. Differential expression of TFFs is observed in pancreatic precursor lesions from
genetically engineered mouse models of PC progression. In addition to pancreatic precursor lesions and tumor tissues, elevated
levels of TFFs were observed in serum samples from early and
late stage PC cases. Combination of TFFs and CA19.9 has improved overall diagnostic accuracy with increased sensitivity and
specificity for detecting early stage of PC in comparison to
CA19.9 alone both in training and independent validation sets.
Implications of all the available evidence
The multimarker panel combining of TFF1, TFF2, TFF3, and
CA19.9 holds the potential to predict the lethal PC at an early
stage. Overall, these findings are clinically relevant, as early diagnostic marker for PC is urgently needed not only for disease detection but also to lead for more targeted approaches for treating
patients with this disease.

1. Introduction
Pancreatic cancer (PC) is an aggressive disease with a ﬁve-year overall survival rate of b8%. It is the third‑leading cause of cancer-related
deaths worldwide, and by 2030, it is projected to escalate to second
rank of cancer-related death [1,2]. While the ﬁve-year survival rate of
patients with localized PC is 34.3%, unfortunately, only 10% of total PC
patients are diagnosed at an early stage. Approximately 52% of cases
are diagnosed at late/metastasized stage, with a worsened ﬁvesurvival rate of only 2.7% [2]. Considering these dire statistics, early detection is key to improved PC patient survival. Therefore, identiﬁcation
of early diagnostic biomarkers may result in a timely therapeutic intervention and lead to improve patient prognosis.
To characterize a prospective diagnostic signature for PC, a compendium of several secretory and membranous proteins was enlisted as potential biomarker candidates that demand methodical validation for
clinical effectivity [3]. Among the identiﬁed 160 secretory molecules,
trefoil factors (TFF1, 2 and 3 (TFFs)) were recognized as potential

markers for PC [3]. TFFs are small, secretory mucin-associated proteins
known to protect epithelial cells from various environmental insults
[4]. Although under physiological conditions they protect the gastric
mucosa from inﬂammation, the oncogenic role of TFFs has been observed in multiple malignancies, including breast, prostate, ovarian,
and colon cancers [5]. The secretory nature of TFFs, and their high resistance to proteolytic digestion, acid, and heat degradation qualify them
as advantageous from a biomarker perspective.
We aimed to explore the individual and combined diagnostic potential of TFFs alone and in combination with CA19.9 in PC. Although they
were previously recognized as promising biomarkers, there has been
no comprehensive study assessing the diagnostic capability of TFFs for
early detection of PC. To evaluate this potential, we explored publicly
available datasets of PC, followed by validation of expression via immunohistochemistry (IHC) in the genetically engineered spontaneous
mouse model of PC progression and human tissues comprising of normal pancreas adjacent to tumor (NAT), PC precursor lesions (PanIN),
and PC tissues. We further evaluated circulatory TFF levels in the sera
obtained from training and validation clinical cohorts of PC patients
and control samples and analyzed the biomarker potential of individual
TFFs in combination with CA19.9. This study reports a potential diagnostic biomarker panel to identify early-stage PC with improved sensitivity
(SN) and speciﬁcity (SP).
2. Materials and methods
2.1. Ethics statement
Training and validation sets were obtained from University of Pittsburgh Medical Center (UPMC, IRB number PRO07030072), with written
consent from all patients before enrollment in the study. Tissue microarrays were obtained from Rapid Autopsy Program (RAP), University
of Nebraska Medical Center (IRB-#091-01) with written consent from
the patients before tissue collection.
2.2. Trefoil factor expression in publicly available PC datasets
GEO datasets containing PC-speciﬁc gene expression and patient
clinical information were used to assess expression of TFFs. Further, to
make the comparisons statistically signiﬁcant and reduce any chance
of method-induced statistical bias, two independent datasets
(GSE16515 and GSE43288) were selected containing normal pancreas,
PanIN, and PC samples. For dataset GSE43288, samples were proﬁled
using Affymetrix Human Genome U133A Array (Affymetrix, Inc., Santa
Clara, CA), which contains normal pancreas (n = 3), PanIN (n = 13)
and PC (n =4) tumor tissues, while dataset GSE16515 samples were
proﬁled using Affymetrix Human Genome U133 Plus 2.0 Array
(Affymetrix, Inc., Santa Clara, CA) and contain normal pancreas (n =
16) and PC (n = 36) tumor tissues [6]. Brieﬂy, the raw CEL ﬁles were
ﬁrst downloaded and background-corrected. Expression was calculated
using the quantile normalization method robust multi-array average
(RMA) within the same package for each dataset. The normalized
gene expression values (RMA) for TFFs in normal, PanIN, and PC were
plotted using MedCalc software. We also analyze all TFFs expression
from cBioPortal database, a freely available dataset which is comprised
of published and provisional TCGA datasets consisting of 169 studies
from 30 different tumor types.
2.3. Tissue immunohistochemistry (IHC) and immunoﬂuorescence for TFF1,
TFF2 and TFF3
Immunohistochemistry analyses were performed on commercial
tissue microarray (TMA) (Biomax, USA) as well as TMA from the rapid
autopsy program (RAP) at UNMC). Tissue spots on the Biomax TMA
(BIC14011, OD-CT-DgPan03-001, OD-CT-DgPan01-006) were examined by their own pathologists to determine the pathological grading
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and staging. This array contained spots from healthy normal or normal
adjacent to the pancreatic tumor, chronic pancreatitis (CP), and PC of
different stages and grades. For immunohistochemical staining of
mouse TFF1, TFF2 and TFF3 in the parafﬁn-embedded mouse tissues,
10, 20, and 30 week old ﬂoxed KrasG12D Pdx1-Cre mouse tissues (positive for both Kras and Pdx1-Cre), and their age-matched littermate controls (n = 3 animals per age group), were processed using methods
describing previously [7]. Brieﬂy, after deparafﬁnization with xylene
and subsequent rehydration with ethanol, epitope retrieval was
achieved by boiling the slides in citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was quenched by immersing the TMAs
in hydrogen peroxidase solution [0.3% hydrogen peroxidase in 1:1 solution of methanol: water] for 1 h. at room temperature, in the dark. Tissues were next blocked with horse serum (ImmPRESS Universal
antibody kit; Vector Laboratories, Burlingame, CA) for 2 h. at room temperature. Subsequently, the TMAs were incubated with individual primary antibodies for TFF1 (1:200, ab92377, Abcam, Cambridge, MA),
TFF2 (Protein tech, 1:500) and TFF3 (ITF Antibody (FL-80): sc-28927,
Santa Cruz for human tissue, for mouse tissue TFF3 antibody was kindly
provided by Daniel K. Podolsky, UT Southwestern Medical Center, Dallas, TX). After overnight incubation with primary antibodies, the slides
were washed four times with PBS, followed by incubation with horseradish peroxidase (HRP)–conjugated secondary antibody (ImmPRESS
Universal antibody kit; Vector Laboratories, Burlingame, CA) for 1 h. Following secondary antibody incubation, the TMAs were washed with
PBS and color was developed using DAB solution (3,3′-diaminobenzidine solution) (DAB substrate kit; Vector Laboratories, Burlingame,
CA). Once the reddishbrown precipitate was developed, the peroxidase
reaction was quenched using distilled water, and sections were counterstained with hematoxylin for 1–2 min. After that, dehydration in an
increasing percentage of ethanol followed by three consecutive washings with xylene were performed. Finally, the sections were mounted
using Vecta-mount mounting medium (Vector Laboratories). Each tissue spot was evaluated by pathologist for the H-score, which is the
product of the percentage of cells positive in the area for each TFF and
intensity of staining on a 0–3 scale (0 = no staining, 1 = weak staining,
2 = moderate staining and 3 = strong staining). Colorectal cancer tissues were used as positive controls and isotype control was used as negative control (image not shown). The slides were scanned with Ventana
iScan HT from (Ventana Medical Systems, Inc.; Roche Group, Tucson,
AZ).
For tissue immunoﬂuorescence studies on TFFs, the initial steps up
to blocking were similar to those of IHC. Following blocking, the slides
were incubated with an appropriate dilution of primary antibodies
(1:25, 1:50 and 1:25 for TFF1, TFF2, and TFF3 respectively, the same antibody used for immunohistochemistry) overnight at 4 °C. Primary antibody detection and visualization of TFF1–3 was achieved by Alexa Fluor
488 labeled goat anti-rabbit IgG2b (Invitrogen Molecular Probes, Eugene, OR, diluted 1:200), incubated for one hour and then washed
with PBS three times. Finally, the sections were mounted using an
anti-fading mounting medium containing DAPI (Vectashield H-1500;
Vector Laboratories). The stained sections were analyzed by confocal
scanning laser microscopy, using an LSM 510 Meta laser scanning microscope (Carl Zeiss, Jena, Germany).
2.4. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA)
Individual TFF levels in serum were measured quantitatively by
sandwich ELISA in accordance with manufacturer instructions, using
the DuoSet ELISA kit with few modiﬁcations (R&D Systems, Catalog
for TFF1: DY5237, for TFF2: DY4077, and for TFF3: DY4407). Before
performing the analysis, assay optimization was performed to select appropriate positive controls and the sample dilution factor to be used for
ELISA. Standard curves were produced from standard provided with the
kit. TFF1 and TFF2 standards were serially (log2) diluted from 250 pg/ml
to 0.4 pg/ml, and TFF3 standard from 750 pg/ml to 1.46 pg/ml. A

3

detailed ELISA protocol is provided in the supplementary section. For
the detection step, instead of using the manufacturer provided
streptavidin-HRP, we used Pierce Streptavidin Poly-HRP (Thermo Scientiﬁc, USA), (diluted to 0.4 μl/ml in 1% BSA) and incubated for 20 min
in the dark at room temperature. ELISA plates were read at 450 nm
with an absorbance correction at 540 nm. Appropriately diluted sample
lysates from TFF expressing cell lines were used as a positive control
(MCF7 breast cancer cells for TFF1, LS174T colon cancer cell line for
TFF2 and AsPC-1 PC cell line for TFF3). According to manufacturer's
datasheet, there is no cross-reactivity across TFFs in ELISA assays.
CA19.9 serum levels were measured using DRG® CA 19–9 ELISA (EIA3940) kit (DRG International, Inc., NJ, USA). Serum samples were diluted
(50 fold) appropriately to obtain absorbance in the linear range of the
assay. The Area Under Curve (AUC) for CA19.9 analysis was performed
with the standard clinical cutoff value (37 U/ml) [8]. All samples were
tested in duplicate. Data were analyzed using SOFTMAX PRO software
(Molecular Devices Corp., Sunnyvale, CA).
2.5. Study cohorts
Two independent sets of samples (training and validation sets) were
used to assess the diagnostic performance of TFFs in PC patient serum.
The training set (n = 304) included benign control (BC, n = 104),
chronic pancreatitis (CP, n = 47), and PC (n = 153). Within the PC
group, samples from early stage (EPC, Stage 1 and 2, n = 80) and late
stage PC (LPC, Stage 3 and 4, n = 73) were segregated for further analysis. Serum samples were shipped from UPMC by overnight mail to the
University of Nebraska Medical Center (UNMC) for all experimental
analyses. PC staging was determined surgically, based on operative pathology, biopsy of metastatic disease, or radiographic imaging studies.
The grade, location of the tumor and stage were based on reviewed hospital records. Patients with benign pathologies such as duodenal ulcers,
choledochocele, common bile duct stones, benign stricture, biliary dilation, or abnormal imaging on computed tomography or magnetic resonance imaging scans of the pancreas were categorized as BC. The
independent blinded validation set was comprised of BC, CP, and PC
for which serum samples were collected and stored at UPMC. In both
training and validation cohort, all samples from UPMC were collected
pretreatment (pre-surgery, pre-chemotherapy). Diagnostic signiﬁcance
of TFFs were further assessed in an independent blinded validation set
(n = 58) containing BC (n = 8), CP (n = 27) and PC (n = 23). In our
validation cohort, the PC samples majorly consisted of EPC (n = 18). Patient demographic information for both training and validation datasets
is included in the Supplementary Table ST1a-b.
2.6. Statistical analysis
Serum concentration of each protein was calculated using GraphPad
software (GraphPad Software, Inc., San Diego, CA). Logarithm transformation was applied to all serum analyses. If the biomarker had a zero
level, before log transformation, the zero was changed to half the next
lowest value for that marker. Biomarker levels were compared among
assay groups with ANOVA. If the overall test was signiﬁcant, then
pairwise comparisons were conducted, adjusting for multiple comparisons with Tukey's method. Patient characteristics were compared by diagnosis using chi-square or Fisher's exact test for categorical variables
and ANOVA for continuous variables. TFF1, TFF2, and TFF3 levels were
compared with patient clinicopathological characteristics using t-tests
or ANOVA. We examined the correlation between markers using Pearson correlation. Univariate and multivariate logistic regression and
ROC curves were used to test individual markers and combinations as
predictors of disease status. ROC curves were used to determine the optimal marker cut points for discriminating the potential of an individual
protein. SAS software version 9.3 was used for data analysis (SAS Institute Inc., Cary, NC).
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3. Results
3.1. Expression of TFFs in PanIN lesions and PC from publicly available cancer genome dataset
We began our exploration with the analysis of TFF1, 2, and 3 expressions in PC using publicly available data sets (GSE43288, GSE16515).
Analyzing both data sets, we observed differential expression of all
TFFs in PanINs and PC compared to normal controls (Fig. 1 a&b). Significant upregulation of TFFs was observed in PanIN (TFF1, P b .005; TFF2, P
b .005 and TFF3 P b .05, Mann-Whitney U Test) as compared to normal
control (Fig. 1a). Similar upregulation of TFFs was observed in PC samples compared to normal control (Fig. 1b). In line with these results,
our analysis of the TCGA genome database from cBioPortal (http://
www.cbioportal.org) also showed that TFFs are widely expressed in a
variety of cancers, predominantly pancreas, colorectal, breast, and prostate (Supplementary Fig. S1a-c) [9,10]. Interestingly, TFF1 was found to
be most differentially expressed in PC followed by breast and other malignancies (Supplementary Fig. S1a). Similarly, the highest expression of
TFF2 was observed in PC followed by colorectal cancer (Supplementary
Fig. S1b). Slightly deviating from TFF1 & TFF2, the highest expression of
TFF3 was observed in colorectal cancer, followed by PC (Supplementary
Fig. S1c). All members of the TFF family were highly expressed in pancreatic tumors, in comparison to other malignancies. Based on the differential upregulation of TFFs from the genomic data, we next sought
to comprehensively analyze the expression of TFFs in a panel of PanIN
and PC tissues as well as in serum samples.
3.2. Expression of TFFs in human clinical samples and spontaneous mouse
model of PC
After observing upregulation of TFFs in PC using available data sets,
we analyzed their expression in TMAs representing human NAT,
PanIN, and PC tissues (Fig. 2a). In corroboration with our genomic
data, we observed signiﬁcant upregulation of all TFFs in PanIN lesions
and different grades of PC. No expression of any TFF was detected in
NAT. Strong expression of TFFs was observed in PanINs, well differentiated (WD), and moderately differentiated (MD) PC tissues, with moderate expression in poorly differentiated (PD) tissues (Fig. 2a). The H-score
of TFFs was found to be signiﬁcantly higher for PanIN I-III (P b .0005 for
TFF1, P b .005 for TFF2 and P b .05 for TFF3), WD (P b .0005 for TFF1, P b
.005 for TFF2 and TFF3) and MD (P b .0005 for TFF1, P b .005 for TFF2 and
TFF3), as compared to normal pancreatic tissue adjacent to tumor (NAT)
(Welch's t-Test) (Fig. 2a). Similar results of differential TFFs expression
in well-differentiated tumor were also observed using immunoﬂuorescence (Supplementary Fig. S2a). We also observed strong positive staining of all TFFs in metastatic liver tissues (5/5) (Supplementary Fig. S2b).
Strong expression of TFF3 was observed in the Islet of Langerhans (Supplementary Fig. S2c) while no expression of other two TFFs were observed. Overall, our results demonstrated elevated expression of all the
TFFs in PanINs, well-differentiated and moderately differentiated tumors in comparison to normal ducts. Given the signiﬁcant overexpression in early stages of PC development, we reasoned that TFFs can
have the potential for early diagnosis of PC, even before the onset of
symptoms. Considering the lack of early-stage tumor tissue, we next analyzed the expression of TFF1, 2, and 3 in a well-characterized spontaneous PC mouse model (KrasG12D; Pdx1-Cre) (KC) that recapitulates
genetic and histopathological features of early stages of PC [11]. Using
IHC analysis, we observed differential expression of all mouse TFF1, 2,
and 3 in KC animal at various weeks representing precursor lesion and
early stage of PC respectively (Fig. 2b).
3.3. Circulating levels of TFFs in clinical samples
To investigate the diagnostic potential of TFFs in PC, we analyzed
their levels in PC patient serum samples, using ELISA. The demographic

and clinical characteristics of patients were detailed in methods and
materials section. The training set is comprised of BC, CP, EPC, and LPC
patient serum samples. We observed that the median serum levels
of TFF1 in patients with BC, CP, EPC, and LPC were 257 pg/ml
(Inter Quartile Range, IQR: 156–616 pg/ml), 270.26 pg/ml (IQR:
185–574 pg/ml), 370.41 pg/ml (IQR: 214–1002 pg/ml), and 303 pg/ml
(IQR: 186–589 pg/ml) respectively. The median serum levels of TFF2
in patients with BC, CP, EPC, and LPC were 3768 pg/ml (IQR:
2510–5322 pg/ml), 3683 pg/ml (IQR: 2679–7450 pg/ml), 5792 pg/ml
(IQR: 3518–8932 pg/ml), and 4807 pg/ml (IQR: 2757–7556 pg/ml), respectively. The median serum levels of TFF3 in patients with BC, CP, EPC,
and LPC were 9348 pg/ml (IQR: 6728–13,223 pg/ml), 11,945 pg/ml
(IQR: 7452–19,149 pg/ml), 11,168 pg/ml (IQR: 7756–19,865 pg/ml),
and 9183 pg/ml (IQR: 6329–14,851 pg/ml), respectively. TFFs levels
are plotted on a logarithm scale (Fig. 3 a-c). The median serum level
of TFF1 was signiﬁcantly higher in EPC as compared to BC (P b .005)
and CP (P b .05, ANOVA) (Fig. 3a). Serum levels of TFF2 were also significantly higher in the EPC group compared to BC and CP (Fig. 3b). In contrast, a signiﬁcant elevation in TFF3 was observed in the CP group
compared to the BC group (P b .01, ANOVA), with no further change observed during PC development (Fig. 3c). Of interest, differential circulating levels of TFFs were observed in late stages of PC as well in
comparison to BC and CP, however, their levels were comparatively
lower than the early stage cases (Fig. 3a-c).
We also investigated the possible correlations between TFFs and
clinicopathological variables such as gender, age, race, bilirubin level,
and alcohol history. No apparent difference was observed in the mean
value of TFF levels across gender, alcohol history, race (African
American, Asian & Caucasian) and bilirubin level. We noted that levels
of TFFs have a strong correlation with age (P b .0001, P = .0004 and P
= .0014 for TFF1, TFF2, and TFF3, respectively, ANOVA) (Supplementary
Table ST2). Circulatory levels of all TFFs were signiﬁcantly high in patients aged N64 (Supplementary Table ST2).

3.4. Diagnostic performance of TFF1-3 individually and in combination in a
training cohort
Considering upregulated expression of TFFs across disease groups,
we next sought to explore their diagnostic potential either alone or in
combination to differentiate various stages of PC from benign controls.
The diagnostic performance of TFFs alone was assessed by using ROC
curve analysis (Table 1). In discriminating BCs from PC, individual TFFs
showed moderate discriminatory potential with SN/SP values for TFF1,
TFF2, and TFF3 being 0.72/0.46, 0.52/0.77 and 0.53/0.64, respectively,
and AUCs 0.61, 0.64, and 0.58, respectively (Table 1, Fig. S3a). For differentiating CP from PC, SN/SP values for TFF1, TFF2, and TFF3 were 0.84/
0.36, 0.68/0.53, and 0.46/0.65, respectively, and AUCs of 0.62, 0.58, and
0.55, respectively (Table 1, Supplementary Fig. S3a). We also analyzed
whether the ratio of circulating individual TFF levels that could differentiate between disease groups. Among all possible ratios, TFF1/TFF3
showed the most promising potential to differentiate between PC vs.
CP (AUC = 0.71) and EPC vs. CP, (AUC = 0.73) (Supplementary
Fig. S3b).
We next analyzed the diagnostic performance of TFFs in combination of two in each group (Supplementary Table ST3a). For this, we
ﬁrst assessed correlation across TFFs and disease group. Our results suggested that the Pearson correlation coefﬁcient was signiﬁcantly higher
between TFF1 and TFF3 (r = 0.514, P = .0003) in the CP group (Supplementary Fig. S4). Interestingly, this dual combination of TFF1 and TFF3
could distinguish PC and EPC from CP, AUCs of 0.71 and 0.72, respectively (Supplementary Table ST3a). As discussed earlier, TFFs has
shown age-dependent variation, we performed the overall analysis
with age-adjustment taking into account those samples who are
N40 years and surprisingly, we have seen combination of TFF1 and
TFF3 made an overall improvement of differentiating PC and EPC from
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Fig. 1. Differential expression of TFF1, TFF2, and TFF3 in PC genomic datasets. (a) Representative box and whisker plots depict the comparison of normalized expression of TFF1–3 mRNA in
GSE43288 dataset across normal pancreas (n = 3), PC precursor lesions i.e. PanIN (n = 13) and pancreatic tumor (PC) tissues (n = 4). (b) Representative box and whisker plots comparing
normalized expression of TFF1–3 mRNA in GSE16515 dataset across normal pancreas (n = 16), and pancreatic tumor tissues (n = 36). The interquartile range (IQR) for TFF1–3 expression
is presented by box and whisker plot (horizontal line represents the 25th percentile, median and 75th percentile and whisker represents 5th and 95th percentile). Publicly available
datasets were obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). Signiﬁcantly elevated expression of all the TFFs were observed in pancreatic tumors.
Further, the elevation in TFFs was found to be signiﬁcantly higher across precursor lesions of PC. P values were determined using the Mann-Whitney U test (two-tailed). Red triangle
represents outlier value.

Fig. 2. Differential expression of TFF1–3 in tissues from precursor lesions, PC tissues from spontaneous PC mouse models and human PC. (a) Immunohistochemical analysis for individual
TFF were performed on pancreatic tissue microarrays (TMAs) containing normal pancreatic tissue adjacent to tumor (NAT) (TFF1, n = 39;TFF2, n = 8; TFF3, n = 41), pancreatic cancer
precursor lesions (PanIN I, II and III), (TFF1, n = 32;TFF2, n = 16; TFF3, n = 10) well-differentiated (WD) (TFF1, n = 13;TFF2, n = 13; TFF3, n = 11), moderately-differentiated (MD) (TFF1,
n = 40;TFF2, n= 40; TFF3, n = 121) and poorly-differentiated (PD) (TFF1, n = 9;TFF2, n = 9;TFF3, n = 10) pancreatic tumor tissues. No expression of TFF1, TFF2, and TFF3 were observed
in normal pancreatic ducts while elevated expression was observed in the ductal compartment across a spectrum of precursor lesions as well as various stages of pancreatic tumor
differentiation. Scale bar for upper represents 500 μm and lower panel magniﬁcation represents 100 μm. Corresponding box and whisker plot representing quantitative H-score for
TFFs expression across NAT, PanINs and pancreatic tumor tissues. Signiﬁcant overexpression of TFFs was observed in pancreatic tumor tissues in comparison to normal pancreas. ***P b
.0005, **P b .005, *P b .05, determined by Welch t-Test. (b) Immunohistochemical analysis of all mouse TFF (mTFF1, mTFF2, & mTFF3) protein expression levels throughout the
progression of PC in the spontaneous KrasG12D Pdx1-Cre (KC) mouse model, from 10 weeks to 30 weeks. Expression of TFF1, TFF2, and TFF3 was progressively increased from 10 to
30 weeks. Scale bars are 100 μm (n = 3 animals/age groups).The interquartile range (IQR) for TFFs expression is presented by corresponding box and whisker plot (Middle horizontal
line represents the median value). *P b .05 is determined by student t-test.
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CP with AUCs of 0.81 and 0.82, respectively (Supplementary
Table ST3b).
A combination of all TFFs demonstrated an AUC of 0.66 (95%CI,
0.59–0.74) with SN/SP 0.73/0.54 to segregate PC from BC. A similar prediction trend was observed for this panel to distinguish EPC from BC.
Compared to any single TFF, the combination panel of TFFs showed signiﬁcant improvement in differentiating PC from CP, with an AUC 0.76
and SN/SP of 0.47/0.92 (Table 2). Similarly, to distinguish early-stage
PC from CP, the panel achieved an AUC value of 0.76 with SN/SP 0.51/
0.90. Values of AUC and sensitivity/speciﬁcity at optimal cutoffs are presented in Table 2. Our analysis suggested that, with age adjustment
combination of all TFFs has shown better performance in differentiating
PC or EPC from CP (AUC of 0.76 without age adjustment and 0.85 with
age adjustment) (Table 2 and Table ST4b). Values of AUC and SN/SP at
optimal cutoffs for dual combinations of TFFs without and with ageadjustment are presented in Supplementary Table ST3a and 3b
respectively.
3.5. The combination of TFFs with CA19.9 improves diagnostic performance
The Pearson correlation coefﬁcient (r) was used to delineate the correlation between TFF and CA19.9 serum levels (Supplementary Fig. S4).
A positive correlation was observed for TFF1 and CA19.9 in BC (r =
0.217, P = .033) and a non signiﬁcant positive correlation observed in
EPC (r = 0.226, P = .6). Signiﬁcant positive correlation was also observed for TFF2 and CA19.9 (r = 0.389, P = .013) in the CP group (Supplementary Fig. S4). Of note, a signiﬁcant negative correlation was
observed between TFF2 and CA19.9 in EPC (r = −0.186, P = .017),
whereas a signiﬁcant positive correlation was observed in LPC (r =
0.276, P = .055). Additionally, a positive but not signiﬁcant correlation
was observed for TFF3 and CA19.9 in all the groups (Supplementary
Fig. S4). Our correlation analysis suggested that these markers can be
complementary to each other in various groups, which can improve
the overall efﬁcacy of diagnosis.
As individual TFF showed moderate discriminatory potential and
positive correlation with CA19.9, we next investigated the diagnostic
performance of all TFF in combination with CA19.9. Our purpose was
to analyze whether various combinations of TFFs can improve the diagnostic ability of CA19.9. CA19.9 differentiated PC from BC with SN/SP
0.86/0.81 (Fig. 4a, Table 2). Combining TFFs with CA19.9 showed improved efﬁciency to distinguish PC from BC with AUC 0.94 (95%CI,
0.87–0.99) compared to CA19.9 alone, AUC 0.91 (95%CI, 0.87–0. 95)

(Fig. 4a, Table 2). Sensitivity also increased from 0.76 to 0.85 (at 90%
speciﬁcity), to discriminate between PC and BC (Table 2). To discriminate between EPC and BC, the panel showed an interesting 10% increase
in sensitivity (at 90% speciﬁcity) compared to CA19.9 alone (Table 2). In
the case of discerning PC from CP, the AUC value escalated from 0.91,
(95%CI 0.86–0.95) to 0.94, (95%CI, 0.90–0.98) (Table 2). The combination of all four markers dramatically improved SN/SP of CA19.9 from
0.87/0.81 to 0.92/0.92 to differentiate EPC from CP (Table 2). Moreover,
a 16% rise in sensitivity (at 90% speciﬁcity) was observed to distinguish
PC from CP. Analysis of EPC and CP also demonstrated a sharp increase
of sensitivity from 0.67 to 0.92 (at 90% speciﬁcity) after the addition of
all TFFs to CA19.9 (Table 2). In the case of differentiating LPC from BC
or CP, the panel reasonably improved sensitivity and speciﬁcity as
well as the overall AUC value (Table 2). AUC values and SN/SP of this
panel for the different groups (at optimal cutoffs as well as sensitivity
at 90% speciﬁcity) for the panel are presented in Table 2. Optimal
cutpoints and models to determine SN/SP for CA19.9 and combination
of TFFs and CA19.9 are presented in Supplementary Table ST4a. Again,
when we analyzed our sample with age-adjustment, we observed similar results to differentiate EPC from CP as compared to without age adjustment (Supplementary Table ST4b). The overall performance of all
possible combination of TFF with CA19.9 without age adjustment are
depicted in Supplementary Fig. S5 and Supplementary Table ST4c.
One of the drawbacks of standard CA 19.9 is that 5–10% people do
not express CA19.9 and therefore possess a risk of false negative results
[12]. Our ﬁnding demonstrates differential correlation between CA19.9
and TFF1–3, which suggests that their addition should complement
CA19.9 to identify PC. In light of this, we next sought to identify the diagnostic role of TFFs in low expressing CA19.9 (b37 U/ml) and high expressing CA19.9 (N37 U/ml) PC patient samples, assuming a likely
possibility that low CA19.9 PC patients are Lewis negative. We grouped
the patients based on the well-established and recommended cut-off
value for CA19.9, 37 U/ml [13]. We found that a combination of
TFF1–3 can better discriminate EPC from BC in low CA19.9 expressing
group, AUC- 0.74, than in high CA19.9 expressing group, AUC 0.69.
(Fig. 4b). The ability to discriminate between EPC and CP was also improved in low vs. high expressing CA19.9 groups, AUC 0.87 vs. 0.71,
and SN/SP 1/0.62 vs. 0.92/0.46 (Fig. 4b, Supplementary Table ST5a and
b). As demonstrated with these correlation and ROC curve results, a
combination of TFF1–3 can complement CA19.9 to determine PC status.
Additionally, as we have observed age-dependent elevation of TFFs,
we performed age-matched analysis of diagnostic potential of TFFs in

Fig. 3. Higher levels of TFF1–3 are present in circulation during the early stages of PC. To evaluate diagnostic signiﬁcance of TFFs, their levels were quantiﬁed in serum from various control
group (benign controls (BC, TFF1, n = 104;TFF2, n = 92; TFF3, n = 98),and chronic pancreatitis (CP, TFF1, n = 47;TFF2, n = 40; TFF3, n = 46) along with early (EPC (Stage 1 and 2, TFF1, n
= 78;TFF2, n = 58; TFF3, n = 77) and late stage PC cases (LPC, stage 3 and 4, TFF1, n = 69;TFF2, n= 52; TFF3, n = 64) using duoset sandwich ELISA assay following manufacturer
instructions (R&D). (a-c) Box and whisker plots showing log [10] transformed serum levels (pg/ml) of TFF1, TFF2 and TFF3 for benign control (BC), chronic pancreatitis (CP), earlystage PC (EPC, stage I and II) and late stage PC (LPC). The plot shows a signiﬁcant increase in serum level of TFF1, TFF2, and TFF3 in EPC group as compared to BC. Box and whisker
limits represent the ﬁfth and 95th percentiles; the box limits represent IQR where the horizontal lines represent 25th, median and 75th percentile the median concentration of each
group. P values are shown above the plots. The P-values were determined by the ANOVA. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1
and 2); LPC, late-stage pancreatic cancer (stage 3 and 4).
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Table 1
Biomarker performance of individual TFF in PC training cohort.
Gene
name

Comparison
groups

Optimal
cutpoint
(pg/ml)

SN (at
optimal
cutpoint)

SP (at
optimal
cutpoint)

p
value

Total
cases

Total
controls

AUC

PPV

NPV

Accuracy

TFF1

PC vs. BC
PC vs. CP
EPC vs BC
EPC vs CP
LPC vs BC
LPC vs CP
PC vs. BC
PC vs. CP
EPC vs BC
EPC vs CP
LPC vs BC
LPC vs CP
PC vs. BC
PC vs. CP
EPC vs BC
EPC vs CP
LPC vs BC
LPC vs CP

N231.71
N162.07
N470.88
N692.43
N184.62
N141.44
N5530.87
N3746.96
N5530.87
N3784.62
N5530.87
N3746.96
N10,761.17
b9818.27
N10,920.53
b11,255.36
N12,878.31
b9590.23

0.72
0.84
0.47
0.38
0.77
0.86
0.52
0.68
0.57
0.71
0.57
0.62
0.53
0.46
0.56
0.52
0.38
0.55

0.46
0.36
0.73
0.87
0.38
0.32
0.77
0.53
0.77
0.53
0.77
0.53
0.64
0.65
0.64
0.57
0.74
0.65

0.0078
0.0035
0.0078
0.0081
0.1751
0.0614
0.0012
0.1840
0.0013
0.0931
0.0617
0.7040
0.0642
0.1692
0.0931
0.5177
0.7995
0.0325

152
152
78
78
69
69
114
114
58
58
52
52
146
146
77
77
64
64

104
47
104
47
104
47
92
40
92
40
92
40
98
46
98
46
98
46

0.61
0.62
0.64
0.65
0.56
0.57
0.64
0.58
0.66
0.61
0.59
0.53
0.58
0.55
0.61
0.52
0.52
0.61

0.66
0.81
0.57
0.83
0.45
0.65
0.74
0.80
0.61
0.68
0.52
0.63
0.69
0.81
0.55
0.66
0.49
0.68

0.52
0.42
0.65
0.46
0.71
0.60
0.56
0.36
0.74
0.55
0.71
0.51
0.48
0.27
0.64
0.41
0.65
0.50

0.61
0.73
0.62
0.57
0.53
0.64
0.63
0.64
0.69
0.63
0.65
0.58
0.57
0.50
0.60
0.53
0.60
0.58

TFF2

TFF3

low and high CA19.9 group. Surprisingly, after age adjustment in both
high and low CA19.9 groups, combination of TFFs has demonstrated
an AUC of 0.92 with SN/SP of 0.80/0.91 to differentiate PC (n = 10)
from CP (n = 23) in low CA19.9 (b37 U/ml) group, whereas, in high
CA19.9 group it showed an AUC of 0.81 with SN/SP 0.83/0.82 to distinguish PC (n = 88) from CP (n = 11) (Supplementary Table ST6a & b).
Improved diagnostic potential to differentiate EPC from BC or CP in
low CA19.9 as compared to high CA19.9 groups by combination of
TFFs is also evident from the analysis (Supplementary Table ST6a & b).

0.85, 0.82 to differentiate PC vs BC, PC vs CP, EPC vs BC and EPC vs CP,
respectively, suggesting that in our validation set also, combination
panel of TFFs has improved the diagnosing ability of CA19.9 in detecting
EPC from BC or CP which corroborates with our earlier result from training set (Supplementary Fig. S6). Sensitivity and speciﬁcity value of individual and combination of TFFs along with CA19.9 using same cutpoint
and models from the training set is shown in Supplementary Table ST7.

3.6. Diagnostic performance of TFF1-3 in the validation cohort

Trefoil Factors have recently emerged as a prominent player in PC
pathogenesis. They have been identiﬁed by multiple individual studies
as top differentially expressed genes in the classical subtype of PC
[14,15]. From the biomarker point of view, TFF1, along with Lymphatic
vessel endothelial hyaluronan receptor 1 (LYVE1) and Regenerating
Family Member 1 Alpha (REG1A), has shown promising results as urinary markers for PC [16]. Moreover, ﬁndings have suggested that TFF1
originates from PC, since its level sharply decreases after surgical removal of the tumor [16]. The potential of TFFs to determine disease status is also well evident in other cancers. For instance, TFF3 has been
demonstrated as a promising biomarker in colorectal cancer and gastric
cancers compared to conventional markers [17–19]. Though TFFs have
been proposed as potential diagnostic markers for PC in many studies,
to our knowledge, there has been no comprehensive study of all trefoil
family members for diagnosing this disease. Here, we analyzed the expression of TFFs along PC progression and evaluated their potential to
improve diagnosis of PC at early stage with better accuracy.
Preclinical exploration of differentially expressed genes from microarray and GEO datasets, in conjunction with previously published reports, suggest that TFFs are differentially upregulated in PC. Our
ﬁndings from cBioportal also showed very high expression of TFF1, 2,
and 3 in PC compared to 30 other malignancies listed in the databases.
Genes and proteins overexpressed in PanIN lesions hold the potential
to detect PC at early stages. While investigating early genetic aberrations during PC pathogenesis, Guo et al. identiﬁed TFF1 overexpression
in the PanIN lesions [20]. Earlier, the transcriptomic analysis also revealed that TFF1 was one of the top upregulated molecules in sporadic
and familial PanINs [21]. This lends credence to the use of TFF1 as a biomarker to identify cystic precursor lesions as well as early stages of PC.
Moreover, elevated expression of all TFF1, 2, and 3 were reported in
intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas
[22]. Using IHC analysis, a signiﬁcant proportion of pancreatic adenocarcinoma cells 23/45 (55%) and ampullary tumor cells, 8/10 (80%) were
shown to overexpress TFF1 [23]. In corroboration with earlier reports,

Next, we performed an independent blinded study for TFFs and
CA19.9 to validate their discriminatory potential in an independent
serum sample cohort consisting of BC (n = 8), CP (n = 27) and PC (n
= 23). We also want to note that, our PC group in validation cohort majorly consisted of EPC (n = 18). In accordance with our earlier results,
we observed the diagnostic performance of combination of all TFFs
with an AUC value of 0.76, 0.84, 0.76, 0.82 in PC vs BC, PC vs CP, EPC
vs BC and EPC vs CP (Supplementary Fig. S6). While in validation set
CA19.9 demonstrated AUC value of 0.85, 0.71, 0.82, 0.66, interestingly
combination of TFFs and CA19.9 showed an AUC value of 0.85, 0.85,
Table 2
Biomarker performance of combination of TFFs and CA19.9 in training cohort.
Assay group

PC vs BC

PC vs CP

EPC vs BC

EPC vs CP

LPC vs BC

LPC vs CP

Prediction models

CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9
CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9
CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9
CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9
CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9
CA19.9
TFF1 + TFF2 + TFF3
TFF1 + TFF2 + TFF3 + CA19.9

Optimal
cutpoint

90% SP

SN

SP

SN

0.86
0.73
0.85
0.88
0.47
0.90
0.84
0.76
0.75
0.87
0.51
0.92
0.82
0.77
0.86
0.81
0.77
0.88

0.81
0.54
0.92
0.81
0.92
0.92
0.81
0.54
0.96
0.81
0.90
0.92
0.95
0.43
0.97
0.96
0.64
0.95

0.76
0.33
0.85
0.74
0.47
0.90
0.69
0.38
0.79
0.67
0.44
0.92
0.82
0.20
0.86
0.82
0.39
0.88

AUC

0.91
0.66
0.94
0.91
0.76
0.94
0.90
0.69
0.93
0.89
0.76
0.93
0.93
0.59
0.95
0.93
0.77
0.96

4. Discussion
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Fig. 4. Evaluation of the diagnostic signiﬁcance of TFFs in combination with CA19.9 (a) To evaluate diagnostic signiﬁcance of the TFFs in combination with CA19.9 for the training set, ROC
curves and AUC analyses was carried out for TFF1, TFF2, TFF3 and is presented to distinguish different control groups from PC. The value of the area under curve (AUC) is represented in
each box. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1 and 2); PC, pancreatic cancer. The ROC curve shows comparable performance
among all individual TFFs to distinguish different control groups from PC. ROC curves and AUC values for the combination of TFF1-3 and CA19.9 to distinguish different control groups
from PC. (b). Evaluation of the diagnostic performance of TFF1-3 in CA19.9 low (b37 U/ml) and high (N37 U/ml) groups. ROC curves and AUC values for the combination of TFF1–3 in
low CA19.9 (b37 U/ml) and high CA19.9 (N37 U/ml) groups, to distinguish different control groups from PC. The value of the area under curve (AUC) is represented in each box. The
ROC curve showed that combination of TFF1–3 retains their diagnostic potential in the setting of low CA19.9, to differentiate between PC and control groups. The AUC is represented in
each box. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1 and 2); PC, pancreatic cancer. The ROC curve showed that combination of TFFs
and CA19.9 has better diagnostic accuracy over CA19.9 to distinguish different control groups from PC as well as EPC.

our study also revealed higher expression of TFFs in well-differentiated
PC tumors compared to undifferentiated tumors [24]. In addition, in our
study strong expression of TFFs in metastatic liver tissues was in agreement with an earlier study by Mofﬁt et al. [15]. While our present work
and other previous studies observed overexpression of TFF3 in the Islets
of Langerhans, the pathophysiological relevance of this overexpression
is still unknown. Serum TFF3 is known to have a proliferative effect on
pancreatic islet β-cells and therefore can therapeutically beneﬁt type 1
and 2 diabetic patients [25]. Also, overexpression of TFF3 in the liver
of diabetic and obese mice was shown to improve glucose tolerance
by decreasing blood glucose levels and inhibiting genes involved in gluconeogenesis [26]. While insulin resistance and glucose intolerance are
associated with PC pathogenesis, it becomes imperative to investigate
the role of TFF3 in diabetes, a well-known risk factor for PC [27]. Of
note, we observed age-dependent increase in TFFs level in PC serum
samples. As PC is an age-dependent disease, the elevated levels in TFFs
level might be due to increasing numbers of PanIN in pancreas [28]. In
this reference, it is also reported earlier that high-grade PanIN lesions
were more likely to be found in older patients and in those with diabetes mellitus [29]. As TFFs are highly expressed in PanIN, so the agedependent increase in PanIN as well as PC progression might be a plausible cause for higher TFFs expression in N64 age. However, in the light
of the lack of tissue samples across various age group, it is very difﬁcult
to say the real reason for elevated TFFs with age. Looking at this trend,
we analyzed TFFs diagnostic performance after age adjustment. Interestingly, combination of all TFFs has shown better performance in differentiating PC or EPC from CP (AUC of 0.76 without age adjustment
and 0.85 with age adjustment) (Table 2, Supplementary Table ST4b).
Additionally, when we adjusted age for both low CA19.9 and high
CA19.9 group, we have observed that combination of TFFs demonstrated AUC value of 0.92 with age adjustment as compared to AUC

value of 0.82 without age adjustment to distinguish PC from CP in low
CA19.9 group, whereas in high CA19.9 group AUC value was 0.81 with
age adjustment as compared to 0.73 without age adjustment to identify
PC from CP (Supplementary Tables ST5a-b and ST6a-b).
Although CA19.9 is by far the most commonly used and standard
biomarker for PC, several drawbacks of CA19.9 persist and limit its
use. These include false negative results in the 5–10% of patients with
a Lewis negative genotype, elevated level in other cancers, and GI diseases [12,30,31]. Multi-marker diagnostic panels have previously
shown promise for many cancers such as breast and CRC [32–35]. Our
group and others investigated the potential of combining CA19.9 with
other biomarkers including intercellular adhesion molecule 1 (ICAM1), osteoprotegerin (OPG), osteopontin (OPN), human epididymis secretory protein 4 (HE4), and neutrophil gelatinase-associated lipocalin
(NGAL) to improve diagnostic performance [36–39]. While all these
studies demonstrated the ability to differentiate PC cases from a healthy
control, they did not prove to be beneﬁcial for prediagnostic risk assessment for PC [37]. Therefore, ongoing efforts to validate the circulating
levels of additional biomarkers which are differentially expressed in
pancreatic tumors and preneoplastic lesions will be beneﬁcial to increase the detection of PC at early stage. Thus, TFFs hold a promise as
a potential biomarker because of their elevated expression in PanIN
and PC. While our results revealed the failure of individual TFFs to discriminate PC from BC, the combination of TFFs with CA19.9 demonstrated a surprisingly better diagnostic performance than CA19.9
alone. In addition, this combination of TFFs with CA19.9 improved the
diagnostic potential of distinguishing EPC, a stage which determines
the possibility of surgical resection, from BC and CP as compared to
CA19.9 alone in both training and validation cohort. Another unique
ﬁnding of our study demonstrated that the combination of TFF1–3 can
differentiate between PC and control groups in patients with low
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CA19.9 expression (b37 U/ml). Taken together, our study suggests the
use of TFF1–3 and CA19.9 combination as a potential diagnostic marker
for PC diagnosis.
The strength of our study is the comprehensive evaluation of TFFs
alone or in combination with CA19.9 as potential PC biomarkers by
employing human tissues, large cohort of serum samples, and the use
of a mouse progression model of PC. While our study strongly suggests
that a combination of TFF1–3 and CA19.9 discriminates early stage PCs
from BCs with improved sensitivity and speciﬁcity, we also observed
decreased TFFs expression in late stages of PC. Though the underlying
mechanisms for this downregulation are still unknown, alteration in
methylation patterns between the well and poorly differentiated PCs
might be one of the reasons [40]. Earlier studies have shown
hypomethylated TFF2 promoter in 84% of PC tissues and treatment
with DNA methyltransferase inhibitor and histone deacetylase inhibitor
in PC cell line, where TFF2 is silenced by methylation, led to the activation of this gene [41]. Recent studies using spontaneous mouse model
demonstrated that loss of TFF1 and TFF2 enhanced PanIN progression
along with PC, which reveals their tumor-suppressing role [42,43].
Nevertheless, TFF1 and TFF2 have been shown to increase PC cell
proliferation and migration [24,44]. Moreover, higher TFF1 expression
was found in central tumors while decreased expression was observed
in the invasion front of human PDAC however, retained TFF1 expression
in the invasion front was associated with positive lymphatic invasion,
lymph node metastasis and poor survival of PC patients [45]. However,
based on our ﬁndings and earlier reports, we believe that TFFs are very
critical factors in PC pathogenesis and that they warrant precise study
with mouse models and in vivo lineage tracing studies.
The limitations of our study include the small sample size of BC in
the validation cohort. Although, analysis in our validation cohort has
demonstrated that combination of TFFs and CA19.9 (AUC = 0.82) improves the overall efﬁcacy of CA19.9 (AUC = 0.66) to differentiate EPC
from CP (Supplementary Fig. S6, Supplementary Table ST7), however,
addition of TFFs could neither add nor reduce the diagnostic power of
CA19.9 to differentiate PC from BC which differed from our analysis in
training set. This ﬁnding further necessitates an extensive blinded validation study with a large number of BC samples in the future. In addition, CA19.9 and TFFs are shown to be elevated in other cancers, but
our study has investigated the diagnostic potential of this biomarker
panel in PC only, and therefore further research in other cancers as
also warranted [5,31]. Furthermore, multi-institutional validation and
cross-validation for this panel are needed to make it a reliable
multimarker panel. Moreover, TFF1 has shown to be a promising urine
biomarker for PC [16]. Based on previous studies and our analysis
from the training and validation sets also suggest that TFF1 should be
given more emphasis for future biomarker and functional studies, as it
performed better in both datasets to differentiate between EPC and
CP. Moreover, it will be interesting to investigate their diagnostic performance in pancreatic juice and urine as well. Alongside the prognostic
signiﬁcance, ability of TFFs to predict recurrence and drug-response in
PC patients, are interesting aspects to investigate in the future as
CA19.9 has been observed to predict post-operative recurrence as well
as response to chemotherapy in PC patients [13]. Another limitation in
our study was a very small sample number in age-adjusted low
CA19.9 (b37 U/ml) group, though our interesting ﬁnding has suggested
that combination of TFFs has the ability to differentiate EPC from CP in
age-adjusted low CA19.9 group with an AUC value of 0.94 (Supplementary Table ST6a). However, considering the limitation of small sample
number and their diagnostic potential in those groups warrants investigating the potential of combination of TFFs in low and high CA19.9
group with age adjustment in a larger cohort of patient sample in future.
Moreover, we have analyzed individual TFFs expression in patient sample BC N 1.2 mg/dL and BC b 1.2 mg/dL samples to identify whether TFFs
can differentiate between non carcinoma and carcinoma related jaundice. We didn't observe any signiﬁcant difference of TFF1 and TFF3 expression with high and low bilirubin levels. At the same time, we
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observed differences in CA19.9 and TFF2 (P b .05, Mann –Whitney U
Test) across these groups suggesting TFF1 or TFF3 could be potential
markers that are not be affected by acute biliary obstructions or noncarcinoma related jaundice. Thus, evaluating TFF 1 and 3 in conjunction
with CA19.9 can improve the performance of the differentiation of noncancer related jaundice or acute biliary obstruction from early stage PC
(Data not shown). Thus, evaluating TFFs clinical utility in differentiating
cancer-related jaundice and non-cancer related jaundiced with a large
cohort of clinical samples would be next logical step as CA19.9 gets elevated even in non-carcinoma conditions like obstructive jaundice and
produce false positive result [46].
To translate this diagnostic panel from bench to bedside, more effort should be made to uncover the molecular landscape of TFFs in
PC. Speciﬁcally, it would be interesting to explore whether increased
levels of TFFs, both in serum and tissue, are the drivers or the consequence of disease progression. TFF1 was previously correlated with
increased PC cell proliferation and metastasis [44], and recombinant
treatment with TFF2 has induced PC cell migration [24]. By contrast,
loss of TFF2 from a newly deﬁned progenitor compartment in PC,
coined the pancreatic duct gland, has shown to accelerate IPMN formation [42].
Recently, Collisson et al. identiﬁed three PC subtypes: classical,
quasi-mesenchymal, and exocrine-like, based on gene signatures
from human and mouse PC samples. They observed that classical
subtype is more gemcitabine-resistant compared to other subtypes
[14]. In another study, the Mofﬁtt group identiﬁed two subgroups,
‘classical’ and ‘basal-like’, where basal-like tumors showed a strong
trend toward a better response to adjuvant therapy. Surprisingly,
both groups have discovered family members of TFFs to be critical
contributors in the classical subtype of PC. Identiﬁcation of PC
subtyping has created a new avenue for PC precision medicine. This
will pave the way to improved clinical outcomes and therapeutic response based on intrinsic molecular variabilities among patient
groups that clinically progress at different rates and may respond differently to administered therapies [14,15]. We believe that
untangling the complex mechanism of PC progression, as well as understanding the genomic landscape of PC subtypes, is thus urgently
required for the development of novel screening strategies and chemopreventive approaches for PC. Uncovering the role of subtypespeciﬁc molecules like TFFs is much needed.
The identiﬁcation of an early diagnostic marker is gaining unprecedented attention not only because it provides insight into disease occurrence but also provides the impetus for developing novel strategies for
therapeutic intervention. Importantly, both our training and validation
sets analysis suggested that combination of TFFs and CA19.9 are able
to differentiate EPC from chronic pancreatitis, a perplexing state
which lead to difﬁculties in identifying PC at early stages. Our combination of TFFs has demonstrated an AUC value of 0.76 (without age adjustment) and 0.85 (with age adjustment) to differentiate EPC, a surgically
resectable stage from CP (Fig. 2 and Supplementary Fig. S4a). Our results
indicated that the combination of CA19.9 and TFFs can differentiate
early stages of pancreatic cancer, which is the stage for surgically resectable pancreatic cancer, from benign controls and chronic pancreatitis.
Thus, we anticipate that combination of TFF1, 2, 3 may not be a useful
marker for identifying tumor resectability with high sensitivity and
speciﬁcity but combination of TFFs and CA19.9 will have the clinical utility for early detection of surgically resectable PC. While still in its infancy, validation of TFFs in combination with CA19.9 in serum will not
only predict the presence of PC at early stage but may also have utility
in stratifying patients for appropriate therapeutic regimen selection,
given that TFFs have been shown to be highly upregulated in classical
subtype of PC. Apart from protein biomarkers, very recently, circulating
tumor DNA (ctDNA), circular RNA, miRNAs, lncRNA, exosomes have
gained immense attention as minimally invasive tool for early detection
and diagnosis of cancer, however efforts are still going on to improve
their isolation techniques, stability, reliability, sensitivity, cost of
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analysis, storage measures for bringing them into clinics [47–50]. Furthermore, recent evidence of conventional biomarker coupled with
KRAS mutations in ctDNA has provided optimism as a diagnostic and
prognostic marker for PC. However, protein-based biomarkers still
stand out as better diagnostics than other emerging biomarkers, primarily because of their superior stability, enhanced availability in the
serum and well-established protocols. More studies are highly desirable
to combine the beneﬁt of both protein-based biomarkers along with genomic marker for diagnosis of lethal PC [51].
Based on our knowledge from the published literature, this study is
the ﬁrst of its kind to demonstrate the potential role of TFF1, TFF2, and
TFF3 as serum-based markers for diagnosing early-stage PC. However,
the establishment of a clinically valuable biomarker panel requires exhaustive validation and cross-sectional multicenter studies, and this is
our ongoing research focus for this panel. Our results suggest compelling evidence from publicly available datasets, tissue, and serum analysis that TFF1, TFF2, and TFF3, along with CA19.9, can be a useful
biomarker for identifying PC.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.03.056.
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